Presentación de un proyecto de investigación: Prevención y tratamiento con fesoterodina de la toxicidad urinaria en pacientes sometidos a radioterapia por cáncer de próstata localizado.

Abstract

Introduction: Radiation cystitis occurs in up to 20% of patients with localized prostate cancer undergoing radiotherapy. Among several lines of treatment, one of the newest and most promising is the instillation of intravesical hyaluronic acid. However, antimuscarinic drugs are commonly administered as symptomatic treatment in routine clinical practice, despite the absence of published data on their effectiveness in this application. Objectives: The aim of this prospective study is to determine whether fesoterodine can prevent or treat radiotherapy-induced genitourinary toxicity in patients with high or intermediate risk of prostate cancer and whether it improves their quality of life. Methods: Patients diagnosed at high or intermediate risk of prostate cancer showing urinary toxicity pre- and post-radiation treatment will be treated with fesoterodine, and their symptoms will be assessed at baseline, three months and one year after starting treatment. Exclusion criteria will be: residual urine over 150 ml, maximum flow lower than 10 ml/s or International Prostate Symptom Score below 8. Results: Data will be analyzed when a sample of 50 patients is reached. The results of our study will be compared with data in the literature on patients who have not received fesoterodine. Conclusions: The aim of this prospective study is to demonstrate the efficacy of fesoterodine to treat residual urinary symptoms in patients with localized prostate cancer after radiation treatment.